恶性胸膜间皮瘤：预测因素与分期
Malignant pleural mesothelioma: predictors and staging.
作者信息
Richards William G
机构信息
Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
出版信息
Ann Transl Med. 2017 Jun;5(11):243. doi: 10.21037/atm.2017.06.26.
Abstract
Malignant pleural mesothelioma remains a rapidly fatal cancer with few effective therapies. Unusual anatomic features complicate determination of stage and prognosis for individual patients. Validation of staging criteria has been difficult given the rarity of the disease and the fact that only a minority of patients undergo surgical resection with pathological examination of their tumors. Thus, additional heuristic factors and algorithms have been taken into account by clinicians to estimate prognosis and inform discussion of appropriate management strategies or clinical research protocols with patients.
摘要
恶性胸膜间皮瘤仍然是一种迅速致命的癌症，有效治疗方法很少。异常的解剖特征使个体患者的分期和预后判定变得复杂。鉴于该疾病的罕见性以及只有少数患者接受肿瘤病理检查的手术切除这一事实，分期标准的验证一直很困难。因此，临床医生已考虑额外的启发式因素和算法来估计预后，并就适当的管理策略或临床研究方案与患者进行讨论。
相似文献
1
Malignant pleural mesothelioma: predictors and staging.
Ann Transl Med. 2017 Jun;5(11):243. doi: 10.21037/atm.2017.06.26.
2
Current surgical management of malignant pleural mesothelioma.
Curr Oncol Rep. 2002 Jul;4(4):354-60. doi: 10.1007/s11912-002-0012-4.
3
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
Chest. 1995 Oct;108(4):1122-8. doi: 10.1378/chest.108.4.1122.
4
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
J Thorac Cardiovasc Surg. 1996 Apr;111(4):815-25; discussion 825-6. doi: 10.1016/s0022-5223(96)70342-2.
5
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
Eur J Cardiothorac Surg. 2011 Aug;40(2):298-303. doi: 10.1016/j.ejcts.2010.12.024. Epub 2011 Feb 9.
6
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J Thorac Cardiovasc Surg. 2005 Jun;129(6):1364-70. doi: 10.1016/j.jtcvs.2004.10.034.
7
[Prognosis, staging and therapy of malignant pleural mesothelioma].
Med Klin (Munich). 2002 Aug 15;97(8):459-71. doi: 10.1007/s00063-002-1181-5.
8
Staging and response to therapy of malignant pleural mesothelioma.
Lung Cancer. 2004 Aug;45 Suppl 1:S59-61. doi: 10.1016/j.lungcan.2004.04.013.
9
Patterns of failure following surgical resection for malignant pleural mesothelioma.
Thorac Surg Clin. 2004 Nov;14(4):567-73. doi: 10.1016/j.thorsurg.2004.06.006.
10
Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma.
Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):356-60.
引用本文的文献
1
The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.
Int J Mol Sci. 2023 Feb 9;24(4):3496. doi: 10.3390/ijms24043496.
2
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study.
JTO Clin Res Rep. 2020 Dec 29;2(3):100135. doi: 10.1016/j.jtocrr.2020.100135. eCollection 2021 Mar.
3
Does size matter? -a population-based analysis of malignant pleural mesothelioma.
Transl Lung Cancer Res. 2020 Aug;9(4):1041-1052. doi: 10.21037/tlcr-19-488.
4
Carbon Nanotubes and Other Engineered Nanoparticles Induced Pathophysiology on Mesothelial Cells and Mesothelial Membranes.
Front Physiol. 2018 Mar 29;9:295. doi: 10.3389/fphys.2018.00295. eCollection 2018.
本文引用的文献
1
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
Cancer Immunol Res. 2016 Dec;4(12):1038-1048. doi: 10.1158/2326-6066.CIR-16-0171. Epub 2016 Nov 14.
2
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2016 Dec;11(12):2100-2111. doi: 10.1016/j.jtho.2016.09.121. Epub 2016 Sep 26.
3
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2016 Dec;11(12):2089-2099. doi: 10.1016/j.jtho.2016.08.147. Epub 2016 Sep 26.
4
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.
J Thorac Oncol. 2016 Dec;11(12):2112-2119. doi: 10.1016/j.jtho.2016.09.124. Epub 2016 Sep 28.
5
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation.
J Thorac Oncol. 2016 Dec;11(12):2082-2088. doi: 10.1016/j.jtho.2016.09.123. Epub 2016 Sep 23.
6
Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).
Wien Klin Wochenschr. 2016 Sep;128(17-18):611-7. doi: 10.1007/s00508-016-1080-z. Epub 2016 Sep 12.
7
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
Ann Thorac Surg. 2016 Oct;102(4):1059-66. doi: 10.1016/j.athoracsur.2016.06.069. Epub 2016 Sep 2.
8
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.
Sci Rep. 2016 Aug 19;6:31745. doi: 10.1038/srep31745.
9
Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
Mol Oncol. 2016 Oct;10(8):1255-65. doi: 10.1016/j.molonc.2016.06.005. Epub 2016 Jun 25.
10
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study.
J Thorac Oncol. 2016 Aug;11(8):1335-1344. doi: 10.1016/j.jtho.2016.04.027. Epub 2016 May 12.
Zotero 插件